Used primarily in cancer research, this compound targets and degrades FLT-3, a protein often mutated in acute myeloid leukemia (AML). By leveraging the PROTAC (Proteolysis Targeting Chimera) technology, it facilitates the breakdown of FLT-3, reducing its levels in cancer cells. This approach helps in inhibiting the growth and survival of leukemia cells, offering a potential therapeutic strategy for FLT-3-driven cancers. It is particularly studied for its ability to overcome resistance to traditional FLT-3 inhibitors, making it a promising candidate for advanced AML treatment.